Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
4Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
FibroBiologics, Inc. (FBLG) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
4Distinct source URLs
10High confidence
0.848Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
FibroBiologics, Inc. Suppliers
Ticker
Name
Confidence
Evidence
H-C-WAINWRIGHT-CO-LLC
H-C-WAINWRIGHT-CO-LLC
92%
As previously disclosed, on May 1, 2026, FibroBiologics, Inc. (the “Company”) entered into that certain At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “…
UNITED-FIRE-CASUALTY-CO
UNITED-FIRE-CASUALTY-CO
92%
On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Grou…
SPINALCYTE-LLC
SPINALCYTE-LLC
90%
In May 2021, as part our formation, we issued the equivalent of 8,750,000 shares of our Series A Preferred Stock to FibroGenesis in exchange for a Patent Assignment Agreement, which assigns certain p…
FIBROGENESIS
FIBROGENESIS
80%
In January 2023, we entered into an Agreement Regarding Right of First Negotiation with FibroGenesis, or the ROFN Agreement
FibroBiologics, Inc. Customers
Ticker
Name
Confidence
Evidence
FIBROGENESIS
FIBROGENESIS
90%
In July 2022, we loaned $300,000 to FibroGenesis at 0% interest and one year maturity date
YORKVILLE
YORKVILLE
90%
The Company may require the investor to purchase up to $ 10.0 million of shares of Common Stock by delivering written notice to the investor.
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
facility related costs and other supplies. We expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received in the future for us…
COMPANY-GOLDEN-KNIGHT-INCORPORATED
COMPANY-GOLDEN-KNIGHT-INCORPORATED
62%
r the three months ended March 31, 2026 and 2025 . Leases The Company determines if an arrangement is a lease at inception. An arrangement is or contains a lease if it conveys the right to control th…
FibroBiologics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
FBLG-DEBT-9439
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
FBLG-DEBT-9438
Warrants outstanding: 6.9
90%
xbrl warrant detail from xbrl 2026-03-31.
FBLG-DEBT
Debt stack $60,000
90%
Market cache reports total debt of $60,000.
FibroBiologics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for FibroBiologics, Inc..
FibroBiologics, Inc. Ownership
Holder
Name
Confidence
Evidence
FBLG-OWNER-BARCLAYS-PLC
BARCLAYS PLC
90%
13F overlay lists BARCLAYS PLC as top holder; 3 tracked holders.
FibroBiologics, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
